Margrit Schwarz

Margrit Schwarz has been a member of the Board of Directors since July 2021. She is the Chief Operating Officer of Draupnir Bio, a biotechnology company in the cardiovascular space. Prior to joining Draupnir Bio, she served as Chief Scientific Officer and Head of R&D at Genevant Sciences, where she was responsible for developing a portfolio of RNAi and mRNA drug candidates in the liver and rare disease space. Previous executive and scientific leadership roles include VP & Global Head External Innovation at Roche, VP & Therapeutic Area Head Cardiorenal at Boehringer Ingelheim, and Director Research at Amgen. Dr Schwarz has led preclinical R&D and IND-enabling phases for multiple development candidates, including the anti-PCSK9 therapeutic antibody Repatha, launched in 2015. She is an Entrepreneur-in-Residence at Novo Seeds, and a contractual Expert with Innosuisse and the European Innovation Council. She has served on the Board of the KERN Conference since 2009, and as strategic advisor to life science incubators in USA and Switzerland since 2018. She holds a PhD in Biochemistry from the University of Cologne, Germany, and an MBA from Columbia University, NY.